Koo,

I agree with Tada that if the DSMB decides that we need more patients, then that is not automatically a bad thing. If we pass the futility analysis at 125 events, I believe that Dr. Sweeney previously said that there is a pre-set sample size analysis at 175 events. If at this analysis they decide we need more patient......then at that point we've already passed the futility analysis and likely we are somewhere in the 20-30% RRR range at least. More patients would be needed just to improve the statistics. A 2400 patient cardiovascular outcomes trial is a small trial.

We've discussed ad nauseum statistics, p-values, different percenatages of relative risk reduction (RRR), etc. for BETonMACE. And usually you are the one asking for clarification. Here are some previous replies of mine to you regarding the importance of statistics vs. the RRR number. 

https://agoracom.com/ir/Resverlogix/forums/discussion/topics/691195-endocrine-news/?message_id=2153461#message

https://agoracom.com/ir/Resverlogix/forums/discussion/topics/667291-consequences-of-betonmace-findings/?message_id=2090124#message

https://agoracom.com/ir/Resverlogix/forums/discussion/topics/667291-consequences-of-betonmace-findings/?message_id=2090213#message